Today we're unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge...

Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…

1.   Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger:  Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…

Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…

Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…